Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CCR8 | P51685 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461559 | 0.87 | ALDH1A1 (0.64) | ALDH1A1KDM4EMEN1KMT2ACCR8 | |
| SCHEMBL15630725 | 0.86 | ALDH1A1 (0.81) | ALDH1A1KDM4EHPGDSMN1; SMN2NPC1 | |
| SCHEMBL15609794 | 0.86 | KDM4E (0.61) | ALDH1A1KDM4EMEN1KMT2ACCR8 | |
| SCHEMBL15609795 | 0.86 | KDM4E (0.61) | ALDH1A1KDM4EMEN1KMT2ACCR8 | |
| SCHEMBL13961307 | 0.82 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDSMN1; SMN2MEN1 | |
| SCHEMBL1506043 | 0.82 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDSMN1; SMN2NPC1 | |
| SCHEMBL11996566 | 0.80 | KDM4E (0.55) | ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL8473671 | 0.80 | KDM4E (0.67) | ALDH1A1KDM4EHPGDSMN1; SMN2NPC1 | |
| SCHEMBL15383657 | 0.80 | ALDH1A1 (0.63) | ALDH1A1KDM4EHPGDSMN1; SMN2NPC1 | |
| SCHEMBL16671210 | 0.79 | KMT2A (0.68) | ALDH1A1KDM4EHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447090-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | GUCY1A1, PDE2A, GUCY1A2 | ALDH1A1 935/4885KDM4E 965/4885HPGD 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.